MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of MEI Pharma (NASDAQ:MEIP) in a report issued on Tuesday. The firm issued a buy rating on the stock.

A number of other research analysts have also recently issued reports on MEIP. TheStreet cut shares of MEI Pharma from a c- rating to a d+ rating in a research report on Thursday, February 1st. Stifel Nicolaus reiterated a hold rating and set a $7.00 target price on shares of MEI Pharma in a report on Friday, April 12th.

MEI Pharma Stock Performance

MEI Pharma stock opened at $3.13 on Tuesday. MEI Pharma has a fifty-two week low of $2.99 and a fifty-two week high of $7.97. The stock’s 50 day simple moving average is $3.64 and its two-hundred day simple moving average is $5.05. The stock has a market cap of $20.85 million, a price-to-earnings ratio of 1.05 and a beta of 0.82.

MEI Pharma (NASDAQ:MEIP) last released its quarterly earnings results on Tuesday, February 13th. The company reported ($1.66) earnings per share for the quarter, missing the consensus estimate of ($1.46) by ($0.20). MEI Pharma had a net margin of 39.06% and a return on equity of 39.72%. On average, analysts predict that MEI Pharma will post 3.24 earnings per share for the current year.

Institutional Investors Weigh In On MEI Pharma

A hedge fund recently bought a new stake in MEI Pharma stock. National Bank of Canada FI acquired a new stake in shares of MEI Pharma, Inc. (NASDAQ:MEIP) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 6,000 shares of the company’s stock, valued at approximately $36,000. National Bank of Canada FI owned about 0.09% of MEI Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 52.38% of the company’s stock.

MEI Pharma Company Profile

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.